Business ❯ Finance ❯ Stock Market ❯ Company Performance

Eli Lilly

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite

Lower U.S. prices, intensifying competition, patent expiries prompted the downgrade.

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

FDA Grants Full Approval to Jaypirca for Relapsed CLL/SLL After Covalent BTK Therapy

Trump Extends U.S.-China Tariff Truce Through November